APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Drug Metabolism and Pharmacokinetics (DMPK) Service

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Analysis and Forecast 2026-2032

Report ID 17412314023 May 2026184 pages

Choose your research edition.

Industry ResearchDrug Metabolism and Pharmacokinetics (DMPK) Service Industry Research Report 2026141 pages · $2,950 USDIndustry Growth & TrendsGlobal Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Drug Metabolism and Pharmacokinetics (DMPK) Service Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drug Metabolism and Pharmacokinetics (DMPK) Service Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drug Metabolism and Pharmacokinetics (DMPK) Service Market Analysis and Forecast 2026-2032184 pages · $4,950 USD

Market perspective

The global Drug Metabolism and Pharmacokinetics (DMPK) Service market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Drug Metabolism and Pharmacokinetics (DMPK) Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Drug Metabolism and Pharmacokinetics (DMPK) Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Drug Metabolism and Pharmacokinetics (DMPK) Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Drug Metabolism and Pharmacokinetics (DMPK) Service is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Drug Metabolism and Pharmacokinetics (DMPK) Service include NuChem Sciences Inc, Sygnature Discovery, Paraza Pharma, Inc, Dalriada, Inotiv, Eurofins Discovery, RTI International, Frontage Labs and Labcorp, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Drug Metabolism and Pharmacokinetics (DMPK) Service, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Drug Metabolism and Pharmacokinetics (DMPK) Service, also provides the revenue of main regions and countries. Of the upcoming market potential for Drug Metabolism and Pharmacokinetics (DMPK) Service, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Drug Metabolism and Pharmacokinetics (DMPK) Service revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Drug Metabolism and Pharmacokinetics (DMPK) Service market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Drug Metabolism and Pharmacokinetics (DMPK) Service revenue, projected growth trends, production technology, application and end-user industry.

Drug Metabolism and Pharmacokinetics (DMPK) Service Segment by Company

NuChem Sciences Inc

Sygnature Discovery

Paraza Pharma, Inc

Dalriada

Inotiv

Eurofins Discovery

RTI International

Frontage Labs

Labcorp

Jubilant Biosys

Creative Biolabs

Evotec

Charles River

Anthem Bio Sciences

Molecular Diagnostic Services, Inc

Invitrocue

TCG Lifesciences Private Limited

Q 2 Solutions

WuXi AppTec

oncodesign service

Alliance Pharma, Inc

QPS Holdings

NUVISAN

Drug Metabolism and Pharmacokinetics (DMPK) Service Segment by Type

In Vivo Drug Metabolism and Pharmacokinetics Services

In Vitro Drug Metabolism and Pharmacokinetics Services

Drug Metabolism and Pharmacokinetics (DMPK) Service Segment by Application

Pharmaceutical Research and Development

Biotechnology

Efficacy Testing

Others

Drug Metabolism and Pharmacokinetics (DMPK) Service Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drug Metabolism and Pharmacokinetics (DMPK) Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drug Metabolism and Pharmacokinetics (DMPK) Service and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drug Metabolism and Pharmacokinetics (DMPK) Service.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Drug Metabolism and Pharmacokinetics (DMPK) Service in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Drug Metabolism and Pharmacokinetics (DMPK) Service company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Drug Metabolism and Pharmacokinetics (DMPK) Service revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. In Vivo Drug Metabolism and Pharmacokinetics Services Major Player Table 3. In Vitro Drug Metabolism and Pharmacokinetics Services Major Player Table 4. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Pharmaceutical Research and Development Major Player Table 6. Biotechnology Major Player Table 7. Efficacy Testing Major Player Table 8. Others Major Player Table 9. Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Trends Table 10. Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Drivers Table 11. Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Opportunities and Challenges Table 12. Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Restraints Table 13. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 14. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Region (2021-2026) & (US$ Million) Table 15. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Share by Region (2021-2026) Table 16. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Region (2027-2032) & (US$ Million) Table 17. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Share by Region (2027-2032) Table 18. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Players (US$ Million) & (2021-2026) Table 19. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Players (2021-2026) Table 20. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Key Players Ranking, 2024 VS 2025 VS 2026 Table 21. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Key Players Headquarters & Area Served Table 22. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Players, Product Type & Application Table 23. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Players Establishment Date Table 24. Global Players Market Concentration Ratio (CR5 and HHI) Table 25. Global Drug Metabolism and Pharmacokinetics (DMPK) Service by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 26. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026) & (US$ Million) Table 28. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032) & (US$ Million) Table 29. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Type (2021-2026) Table 30. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Type (2027-2032) Table 31. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026) & (US$ Million) Table 33. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032) & (US$ Million) Table 34. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Application (2021-2026) Table 35. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Application (2027-2032) Table 36. NuChem Sciences Inc Company Information Table 37. NuChem Sciences Inc Business Overview Table 38. NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 40. NuChem Sciences Inc Recent Development Table 41. Sygnature Discovery Company Information Table 42. Sygnature Discovery Business Overview Table 43. Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 45. Sygnature Discovery Recent Development Table 46. Paraza Pharma, Inc Company Information Table 47. Paraza Pharma, Inc Business Overview Table 48. Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 50. Paraza Pharma, Inc Recent Development Table 51. Dalriada Company Information Table 52. Dalriada Business Overview Table 53. Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 55. Dalriada Recent Development Table 56. Inotiv Company Information Table 57. Inotiv Business Overview Table 58. Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 60. Inotiv Recent Development Table 61. Eurofins Discovery Company Information Table 62. Eurofins Discovery Business Overview Table 63. Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 65. Eurofins Discovery Recent Development Table 66. RTI International Company Information Table 67. RTI International Business Overview Table 68. RTI International Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. RTI International Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 70. RTI International Recent Development Table 71. Frontage Labs Company Information Table 72. Frontage Labs Business Overview Table 73. Frontage Labs Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. Frontage Labs Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 75. Frontage Labs Recent Development Table 76. Labcorp Company Information Table 77. Labcorp Business Overview Table 78. Labcorp Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Labcorp Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 80. Labcorp Recent Development Table 81. Jubilant Biosys Company Information Table 82. Jubilant Biosys Business Overview Table 83. Jubilant Biosys Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Jubilant Biosys Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 85. Jubilant Biosys Recent Development Table 86. Creative Biolabs Company Information Table 87. Creative Biolabs Business Overview Table 88. Creative Biolabs Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 89. Creative Biolabs Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 90. Creative Biolabs Recent Development Table 91. Evotec Company Information Table 92. Evotec Business Overview Table 93. Evotec Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. Evotec Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 95. Evotec Recent Development Table 96. Charles River Company Information Table 97. Charles River Business Overview Table 98. Charles River Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Charles River Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 100. Charles River Recent Development Table 101. Anthem Bio Sciences Company Information Table 102. Anthem Bio Sciences Business Overview Table 103. Anthem Bio Sciences Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Anthem Bio Sciences Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 105. Anthem Bio Sciences Recent Development Table 106. Molecular Diagnostic Services, Inc Company Information Table 107. Molecular Diagnostic Services, Inc Business Overview Table 108. Molecular Diagnostic Services, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Molecular Diagnostic Services, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 110. Molecular Diagnostic Services, Inc Recent Development Table 111. Invitrocue Company Information Table 112. Invitrocue Business Overview Table 113. Invitrocue Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Invitrocue Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 115. Invitrocue Recent Development Table 116. TCG Lifesciences Private Limited Company Information Table 117. TCG Lifesciences Private Limited Business Overview Table 118. TCG Lifesciences Private Limited Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 119. TCG Lifesciences Private Limited Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 120. TCG Lifesciences Private Limited Recent Development Table 121. Q 2 Solutions Company Information Table 122. Q 2 Solutions Business Overview Table 123. Q 2 Solutions Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 124. Q 2 Solutions Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 125. Q 2 Solutions Recent Development Table 126. WuXi AppTec Company Information Table 127. WuXi AppTec Business Overview Table 128. WuXi AppTec Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 129. WuXi AppTec Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 130. WuXi AppTec Recent Development Table 131. oncodesign service Company Information Table 132. oncodesign service Business Overview Table 133. oncodesign service Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 134. oncodesign service Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 135. oncodesign service Recent Development Table 136. Alliance Pharma, Inc Company Information Table 137. Alliance Pharma, Inc Business Overview Table 138. Alliance Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 139. Alliance Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 140. Alliance Pharma, Inc Recent Development Table 141. QPS Holdings Company Information Table 142. QPS Holdings Business Overview Table 143. QPS Holdings Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 144. QPS Holdings Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 145. QPS Holdings Recent Development Table 146. NUVISAN Company Information Table 147. NUVISAN Business Overview Table 148. NUVISAN Drug Metabolism and Pharmacokinetics (DMPK) Service Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 149. NUVISAN Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio Table 150. NUVISAN Recent Development Table 151. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026) & (US$ Million) Table 152. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032) & (US$ Million) Table 153. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026) & (US$ Million) Table 154. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032) & (US$ Million) Table 155. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 156. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021-2026) & (US$ Million) Table 157. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (US$ Million) & (2027-2032) Table 158. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026) & (US$ Million) Table 159. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032) & (US$ Million) Table 160. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026) & (US$ Million) Table 161. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032) & (US$ Million) Table 162. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 163. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021-2026) & (US$ Million) Table 164. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (US$ Million) & (2027-2032) Table 165. China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026) & (US$ Million) Table 166. China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032) & (US$ Million) Table 167. China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026) & (US$ Million) Table 168. China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032) & (US$ Million) Table 169. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026) & (US$ Million) Table 170. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032) & (US$ Million) Table 171. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026) & (US$ Million) Table 172. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032) & (US$ Million) Table 173. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 174. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Region (US$ Million) & (2021-2026) Table 175. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Region (US$ Million) & (2027-2032) Table 176. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026) & (US$ Million) Table 177. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032) & (US$ Million) Table 178. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026) & (US$ Million) Table 179. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032) & (US$ Million) Table 180. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021-2026) & (US$ Million) Table 182. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (US$ Million) & (2027-2032) Table 183. Research Programs/Design for This Report Table 184. Authors List of This Report Table 185. Secondary Sources Table 186. Primary Sources List of Figures Figure 1. Drug Metabolism and Pharmacokinetics (DMPK) Service Image Figure 2. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Share 2021 VS 2025 VS 2032 Figure 4. In Vivo Drug Metabolism and Pharmacokinetics Services Image Figure 5. In Vitro Drug Metabolism and Pharmacokinetics Services Image Figure 6. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size Share 2021 VS 2025 VS 2032 Figure 8. Pharmaceutical Research and Development Image Figure 9. Biotechnology Image Figure 10. Efficacy Testing Image Figure 11. Others Image Figure 12. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size (US$ Million) & (2021-2032) Figure 13. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Share by Region: 2021 VS 2025 VS 2032 Figure 15. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Players Revenue Share Top 10 and Top 5 in 2025 Figure 16. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 17. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share 2021 VS 2025 VS 2032 Figure 19. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Type (2021-2032) Figure 20. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 21. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 22. Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Application (2021-2032) Figure 23. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 24. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032) Figure 25. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032) Figure 26. North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Country (2021-2032) Figure 27. United States Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Canada Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Mexico Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 31. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032) Figure 32. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032) Figure 33. Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Country (2021-2032) Figure 34. Germany Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. France Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. U.K. Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Italy Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Spain Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Russia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Netherlands Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Nordic Countries Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 43. China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032) Figure 44. China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032) Figure 45. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 46. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032) Figure 47. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032) Figure 48. Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Region (2021-2032) Figure 49. Japan Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. South Korea Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. India Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Australia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Taiwan Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Southeast Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (2021-2032) & (US$ Million) Figure 56. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032) Figure 57. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032) Figure 58. SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Country (2021-2032) Figure 59. Brazil Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Argentina Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Chile Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Colombia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Peru Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Saudi Arabia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Israel Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. UAE Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Turkey Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Iran Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Egypt Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • In Vivo Drug Metabolism and Pharmacokinetics Services
  • In Vitro Drug Metabolism and Pharmacokinetics Services
Applications
  • Pharmaceutical Research and Development
  • Biotechnology
  • Efficacy Testing
  • Others
Companies covered
  • NuChem Sciences Inc
  • Sygnature Discovery
  • Paraza Pharma, Inc
  • Dalriada
  • Inotiv
  • Eurofins Discovery
  • RTI International
  • Frontage Labs
  • Labcorp
  • Jubilant Biosys
  • Creative Biolabs
  • Evotec
  • Charles River
  • Anthem Bio Sciences
  • Molecular Diagnostic Services, Inc
  • Invitrocue
  • TCG Lifesciences Private Limited
  • Q 2 Solutions
  • WuXi AppTec
  • oncodesign service
  • Alliance Pharma, Inc
  • QPS Holdings
  • NUVISAN

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Drug Metabolism and Pharmacokinetics (DMPK) Service Market by Type
  3. 1.2.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 In Vivo Drug Metabolism and Pharmacokinetics Services
  5. 1.2.3 In Vitro Drug Metabolism and Pharmacokinetics Services
  6. 1.3 Drug Metabolism and Pharmacokinetics (DMPK) Service Market by Application
  7. 1.3.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Pharmaceutical Research and Development
  9. 1.3.3 Biotechnology
  10. 1.3.4 Efficacy Testing
  11. 1.3.5 Others
  12. 1.4 Assumptions and Limitations
  13. 1.5 Study Goals and Objectives
2 Drug Metabolism and Pharmacokinetics (DMPK) Service Market Dynamics
  1. 2.1 Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Trends
  2. 2.2 Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Drivers
  3. 2.3 Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Opportunities and Challenges
  4. 2.4 Drug Metabolism and Pharmacokinetics (DMPK) Service Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Perspective (2021-2032)
  2. 3.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Growth Trends by Region
  3. 3.2.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Region (2021-2026)
  5. 3.2.3 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Players
  2. 4.1.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Players (2021-2026)
  3. 4.1.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Key Players Headquarters & Area Served
  7. 4.4 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Players, Product Type & Application
  8. 4.5 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Market CR5 and HHI
  11. 4.6.3 2025 Drug Metabolism and Pharmacokinetics (DMPK) Service Tier 1, Tier 2, and Tier 3
5 Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Type
  1. 5.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2032)
  3. 5.3 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Type (2021-2032)
6 Drug Metabolism and Pharmacokinetics (DMPK) Service Market Size by Application
  1. 6.1 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2032)
  3. 6.3 Global Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 NuChem Sciences Inc
  2. 7.1.1 NuChem Sciences Inc Company Information
  3. 7.1.2 NuChem Sciences Inc Business Overview
  4. 7.1.3 NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  5. 7.1.4 NuChem Sciences Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  6. 7.1.5 NuChem Sciences Inc Recent Developments
  7. 7.2 Sygnature Discovery
  8. 7.2.1 Sygnature Discovery Company Information
  9. 7.2.2 Sygnature Discovery Business Overview
  10. 7.2.3 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sygnature Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  12. 7.2.5 Sygnature Discovery Recent Developments
  13. 7.3 Paraza Pharma, Inc
  14. 7.3.1 Paraza Pharma, Inc Company Information
  15. 7.3.2 Paraza Pharma, Inc Business Overview
  16. 7.3.3 Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Paraza Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  18. 7.3.5 Paraza Pharma, Inc Recent Developments
  19. 7.4 Dalriada
  20. 7.4.1 Dalriada Company Information
  21. 7.4.2 Dalriada Business Overview
  22. 7.4.3 Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Dalriada Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  24. 7.4.5 Dalriada Recent Developments
  25. 7.5 Inotiv
  26. 7.5.1 Inotiv Company Information
  27. 7.5.2 Inotiv Business Overview
  28. 7.5.3 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Inotiv Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  30. 7.5.5 Inotiv Recent Developments
  31. 7.6 Eurofins Discovery
  32. 7.6.1 Eurofins Discovery Company Information
  33. 7.6.2 Eurofins Discovery Business Overview
  34. 7.6.3 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Eurofins Discovery Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  36. 7.6.5 Eurofins Discovery Recent Developments
  37. 7.7 RTI International
  38. 7.7.1 RTI International Company Information
  39. 7.7.2 RTI International Business Overview
  40. 7.7.3 RTI International Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  41. 7.7.4 RTI International Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  42. 7.7.5 RTI International Recent Developments
  43. 7.8 Frontage Labs
  44. 7.8.1 Frontage Labs Company Information
  45. 7.8.2 Frontage Labs Business Overview
  46. 7.8.3 Frontage Labs Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Frontage Labs Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  48. 7.8.5 Frontage Labs Recent Developments
  49. 7.9 Labcorp
  50. 7.9.1 Labcorp Company Information
  51. 7.9.2 Labcorp Business Overview
  52. 7.9.3 Labcorp Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Labcorp Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  54. 7.9.5 Labcorp Recent Developments
  55. 7.10 Jubilant Biosys
  56. 7.10.1 Jubilant Biosys Company Information
  57. 7.10.2 Jubilant Biosys Business Overview
  58. 7.10.3 Jubilant Biosys Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Jubilant Biosys Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  60. 7.10.5 Jubilant Biosys Recent Developments
  61. 7.11 Creative Biolabs
  62. 7.11.1 Creative Biolabs Company Information
  63. 7.11.2 Creative Biolabs Business Overview
  64. 7.11.3 Creative Biolabs Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Creative Biolabs Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  66. 7.11.5 Creative Biolabs Recent Developments
  67. 7.12 Evotec
  68. 7.12.1 Evotec Company Information
  69. 7.12.2 Evotec Business Overview
  70. 7.12.3 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Evotec Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  72. 7.12.5 Evotec Recent Developments
  73. 7.13 Charles River
  74. 7.13.1 Charles River Company Information
  75. 7.13.2 Charles River Business Overview
  76. 7.13.3 Charles River Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Charles River Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  78. 7.13.5 Charles River Recent Developments
  79. 7.14 Anthem Bio Sciences
  80. 7.14.1 Anthem Bio Sciences Company Information
  81. 7.14.2 Anthem Bio Sciences Business Overview
  82. 7.14.3 Anthem Bio Sciences Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  83. 7.14.4 Anthem Bio Sciences Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  84. 7.14.5 Anthem Bio Sciences Recent Developments
  85. 7.15 Molecular Diagnostic Services, Inc
  86. 7.15.1 Molecular Diagnostic Services, Inc Company Information
  87. 7.15.2 Molecular Diagnostic Services, Inc Business Overview
  88. 7.15.3 Molecular Diagnostic Services, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  89. 7.15.4 Molecular Diagnostic Services, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  90. 7.15.5 Molecular Diagnostic Services, Inc Recent Developments
  91. 7.16 Invitrocue
  92. 7.16.1 Invitrocue Company Information
  93. 7.16.2 Invitrocue Business Overview
  94. 7.16.3 Invitrocue Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  95. 7.16.4 Invitrocue Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  96. 7.16.5 Invitrocue Recent Developments
  97. 7.17 TCG Lifesciences Private Limited
  98. 7.17.1 TCG Lifesciences Private Limited Company Information
  99. 7.17.2 TCG Lifesciences Private Limited Business Overview
  100. 7.17.3 TCG Lifesciences Private Limited Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  101. 7.17.4 TCG Lifesciences Private Limited Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  102. 7.17.5 TCG Lifesciences Private Limited Recent Developments
  103. 7.18 Q 2 Solutions
  104. 7.18.1 Q 2 Solutions Company Information
  105. 7.18.2 Q 2 Solutions Business Overview
  106. 7.18.3 Q 2 Solutions Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  107. 7.18.4 Q 2 Solutions Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  108. 7.18.5 Q 2 Solutions Recent Developments
  109. 7.19 WuXi AppTec
  110. 7.19.1 WuXi AppTec Company Information
  111. 7.19.2 WuXi AppTec Business Overview
  112. 7.19.3 WuXi AppTec Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  113. 7.19.4 WuXi AppTec Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  114. 7.19.5 WuXi AppTec Recent Developments
  115. 7.20 oncodesign service
  116. 7.20.1 oncodesign service Company Information
  117. 7.20.2 oncodesign service Business Overview
  118. 7.20.3 oncodesign service Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  119. 7.20.4 oncodesign service Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  120. 7.20.5 oncodesign service Recent Developments
  121. 7.21 Alliance Pharma, Inc
  122. 7.21.1 Alliance Pharma, Inc Company Information
  123. 7.21.2 Alliance Pharma, Inc Business Overview
  124. 7.21.3 Alliance Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  125. 7.21.4 Alliance Pharma, Inc Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  126. 7.21.5 Alliance Pharma, Inc Recent Developments
  127. 7.22 QPS Holdings
  128. 7.22.1 QPS Holdings Company Information
  129. 7.22.2 QPS Holdings Business Overview
  130. 7.22.3 QPS Holdings Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  131. 7.22.4 QPS Holdings Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  132. 7.22.5 QPS Holdings Recent Developments
  133. 7.23 NUVISAN
  134. 7.23.1 NUVISAN Company Information
  135. 7.23.2 NUVISAN Business Overview
  136. 7.23.3 NUVISAN Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue and Gross Margin (2021-2026)
  137. 7.23.4 NUVISAN Drug Metabolism and Pharmacokinetics (DMPK) Service Product Portfolio
  138. 7.23.5 NUVISAN Recent Developments
8 North America
  1. 8.1 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2021-2032)
  2. 8.2 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2032)
  3. 8.2.1 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026)
  4. 8.2.2 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032)
  5. 8.3 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032)
  6. 8.4 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2032)
  7. 8.4.1 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026)
  8. 8.4.2 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032)
  9. 8.5 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032)
  10. 8.6 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country
  11. 8.6.1 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021-2026)
  13. 8.6.3 North America Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2021-2032)
  2. 9.2 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2032)
  3. 9.2.1 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026)
  4. 9.2.2 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032)
  5. 9.3 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032)
  6. 9.4 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2032)
  7. 9.4.1 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026)
  8. 9.4.2 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032)
  9. 9.5 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032)
  10. 9.6 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country
  11. 9.6.1 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021-2026)
  13. 9.6.3 Europe Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2021-2032)
  2. 10.2 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2032)
  3. 10.2.1 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026)
  4. 10.2.2 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032)
  5. 10.3 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032)
  6. 10.4 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2032)
  7. 10.4.1 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026)
  8. 10.4.2 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032)
  9. 10.5 China Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2021-2032)
  2. 11.2 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2032)
  3. 11.2.1 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026)
  4. 11.2.2 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032)
  5. 11.3 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032)
  6. 11.4 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2032)
  7. 11.4.1 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026)
  8. 11.4.2 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032)
  9. 11.5 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032)
  10. 11.6 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country
  11. 11.6.1 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021-2026)
  13. 11.6.3 Asia Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue (2021-2032)
  2. 12.2 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Type (2027-2032)
  5. 12.3 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Application (2027-2032)
  9. 12.5 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country
  11. 12.6.1 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Drug Metabolism and Pharmacokinetics (DMPK) Service Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst